|
|
|
|
|
|
|
M T W Thu F |
|
20 August, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
It’s called the “gray market,” but a new study's conclusions are black and white: Illegally sold versions of Lilly's triple-action weight loss drug retatrutide don’t work as well as the real thing. Elizabeth Cairns has the details. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Elizabeth Cairns
|
Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of up to 25%... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about AC Immune, Lilly's Adverum and SiranBio. 🤝 Eli Lilly signs vaccine deal with Amplitude: The companies will work to developvaccines using... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Ultragenyx has secured its first approved gene therapy, with the FDA clearing its asset for an ultra-rare disease that can cause life-threatening blood sugar crashes... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
Regeneron has secured approval for its treatment for a debilitating disease that replaces muscle and connective tissue with bone. The FDA on Wednesday cleared the... | |
|
|
|
|
|
|
|
